Intercepting EV-mediated intercellular communication in the tumor niches (i.e., primary and secondary sites) with an anti-CD9 Fab, combined with direct targeting of cancer cells, could lead to the development of new anti-cancer therapeutic strategies. Here, CD9 is linked to cancer.